Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Keating

Showing results (271-280 of 436) with videos related to

Pageof 44
Sort By:
Blood|June 15, 1996
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatmentB D Cheson, J M Bennett, M Grever, et al.
Cancer|November 1, 1985
Subacute pulmonary failure complicating therapy with high-dose Ara-C in acute leukemiaB S Andersson, B M Cogan, M J Keating, et al.
Blood|June 1, 1993
Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agentM J Keating, S O'Brien, H Kantarjian, et al.
Leukemia & Lymphoma|March 18, 2000
Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemiaM J Keating, T L Smith, S Lerner, et al.
Acta Haematologica|January 1, 1987
Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemiaH M Kantarjian, M Talpaz, R Kurzrock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Second cancer risk in hairy cell leukemia: analysis of 350 patientsR Kurzrock, S S Strom, E Estey, et al.
The American Journal of Medicine|February 1, 1991
Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemiaH M Kantarjian, C Childs, S O'Brien, et al.
Cancer|October 15, 1986
Early intensification and short-term maintenance chemotherapy does not prolong survival in acute myelogenous leukemiaH M Kantarjian, M J Keating, R S Walters, et al.
Blood|July 1, 1985
Preferential expression of double-stranded ribonucleic acid in tumor versus normal cells: biological and clinical implicationsH M Kantarjian, B Barlogie, M Pershouse, et al.
Leukemia|January 1, 1992
Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991M J Keating, E Estey, H Kantarjian, et al.
Pageof 44

Showing results (271-280 of 436) with videos related to

Sort By:
Pageof 44
Blood|June 15, 1996
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatmentB D Cheson, J M Bennett, M Grever, et al.
Cancer|November 1, 1985
Subacute pulmonary failure complicating therapy with high-dose Ara-C in acute leukemiaB S Andersson, B M Cogan, M J Keating, et al.
Blood|June 1, 1993
Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agentM J Keating, S O'Brien, H Kantarjian, et al.
Leukemia & Lymphoma|March 18, 2000
Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemiaM J Keating, T L Smith, S Lerner, et al.
Acta Haematologica|January 1, 1987
Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemiaH M Kantarjian, M Talpaz, R Kurzrock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Second cancer risk in hairy cell leukemia: analysis of 350 patientsR Kurzrock, S S Strom, E Estey, et al.
The American Journal of Medicine|February 1, 1991
Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemiaH M Kantarjian, C Childs, S O'Brien, et al.
Cancer|October 15, 1986
Early intensification and short-term maintenance chemotherapy does not prolong survival in acute myelogenous leukemiaH M Kantarjian, M J Keating, R S Walters, et al.
Blood|July 1, 1985
Preferential expression of double-stranded ribonucleic acid in tumor versus normal cells: biological and clinical implicationsH M Kantarjian, B Barlogie, M Pershouse, et al.
Leukemia|January 1, 1992
Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991M J Keating, E Estey, H Kantarjian, et al.
Pageof 44